scholarly journals Association between ambient fine particulate matters and chronic obstructive pulmonary disease (COPD) mortality: an analysis in Southeastern China

2020 ◽  
Author(s):  
Zhijian Chen ◽  
Qiuli Fu ◽  
Guangming Mao ◽  
Lizhi Wu ◽  
Peiwei Xu ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Mixed Model ◽  
Fine Particles ◽  
Chronic Obstructive ◽  
Particulate Matters ◽  
Southeastern China ◽  
Obstructive Pulmonary Disease ◽  
Adverse Health Effects ◽  
Copd Mortality

Abstract Background: The objective of this study was to investigate the association between ambient particulate matters(PMs)and chronic obstructive pulmonary disease (COPD) mortality.Methods: Generalized Additive Mixed Model was employed to investigate the effects of ambient fine and coarse PMs on COPD mortality using 13,066 deaths from 2014 to 2016 among six cities in Zhejiang Province in Southeastern China.Results: The daily average death count due to COPD was 3, varying from 1 to 7among six cities. The daily 24-hour mean concentrations were diverse among cities, from 29.7 to 56.8 µg/m3 for PM2.5, 16.7 to 30.3 µg/m3 for PM2.5−10, and 50.3 to 87.1 µg/m3 for PM10, respectively. The analysis showed that daily exposure to PM2.5 and PM10 was associated with increased mortality due to COPD and that weak effects were observed between PM2.5−10 and COPD mortality.Conclusions: Our results provided evidence that the fine particles in air pollution have stronger functions on adverse health effects other than coarser particles in Southeastern China, which may be considered as a potential clinic target in PM-associated COPD.

Effects of post-discharge telemonitoring on 30-day chronic obstructive pulmonary disease readmissions and mortality

2020 ◽  
pp. 1357633X2097040
Author(s):  
Hanadi Y Hamadi ◽  
Dayana Martinez ◽  
Jing Xu ◽  
Geoffrey A Silvera ◽  
Jorge M Mallea ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Mortality Rates ◽  
Care Quality ◽  
Chronic Obstructive ◽  
Post Discharge ◽  
Obstructive Pulmonary Disease ◽  
American Hospital ◽  
American Hospital Association ◽  
Copd Mortality

Introduction Much attention has been focused on decreasing chronic obstructive pulmonary disease (COPD) hospital readmissions. The US health system has struggled to meet this goal. The objective of this study was to assess the efficacy of telehealth services on the reduction of hospital readmission and mortality rates for COPD. Methods We used a cross-sectional design to examine the association between hospital risk-adjusted readmission and mortality rates for COPD and hospital use of post-discharge telemonitoring (TM). Data for 777 hospitals were sourced from the Centers for Medicare & Medicaid Services and the American Hospital Association annual surveys. Propensity score matching using the kennel weights method was applied to calculate the weighted probability of being a hospital that offers post-discharge TM services. Results Hospitals with post-discharge TM had about 34% significantly higher odds (adjusted odds ratio (AOR) = 1.34; 95% confidence interval (CI) 1.06–1.70) of 30-day COPD readmission and 33% significantly lower odds (AOR = 0.67; 95% CI 0.50–0.90) of 30-day COPD mortality compared to hospitals without post-discharge TM services. Discussion Overall, hospitals that offer post-discharge TM services have seen an improvement in 30-day COPD mortality rates. However, those same hospitals have also experienced a significant increase in 30-day COPD readmissions. TM can potentially decrease mortality in patients recently admitted for acute exacerbation of COPD. The results provide further evidence that readmissions present a problematic assessment of health-care quality, as the need for readmission may or may not be directly related to the quality of care received while in hospital.

scholarly journals Mortality trends due to chronic obstructive pulmonary disease in Brazil

2014 ◽  
Vol 60 (3) ◽  
pp. 255-261 ◽  
Author(s):  
Gustavo Silveira Graudenz ◽  
Gabriel Pereira Gazotto
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Polynomial Regression ◽  
Functional Relation ◽  
Mortality Rates ◽  
Chronic Obstructive ◽  
Mortality Trends ◽  
Obstructive Pulmonary Disease ◽  
Increasing Trend ◽  
Copd Mortality

Objective: the purpose of this study was to update and analyze data on mortality trend due to chronic obstructive pulmonary disease (COPD) in Brazil. Methods: initially, the specific COPD mortality rates were calculated from 1989 to 2009 using data collected from DATASUS (Departamento de Informática do SUS - Brazilian Health System Database). Then, the polynomial regression models from the observed functional relation were estimated based on mortality coefficients and study years. Results: we verified that the general mortality rates due to COPD in Brazil showed an increasing trend from 1989 to 2004, and then decreased. Both genders showed the same increasing tendencies until 2004 and decreased thereafter. The age group under 35 years old showed a linear decreasing trend. All other age groups showed quadratic tendencies, with increases until the years of 1998-1999 and then decreasing. The South and Southeast regions showed the highest COPD mortality rates with increasing trends until the years 2001-2002 and then decreased. The North, Northeast and Central-West regions showed lower mortality rates but increasing trend. Conclusion: this is the first report of COPD mortality stabilization in Brazil since 1980.

scholarly journals Effect of Nocturnal Oxygen Therapy on Daytime Pulmonary Hemodynamics in Patients With Chronic Obstructive Pulmonary Disease Traveling to Altitude: A Randomized Controlled Trial

2021 ◽  
Vol 12 ◽  
Author(s):  
Mona Lichtblau ◽  
Tsogyal D. Latshang ◽  
Sayaka S. Aeschbacher ◽  
Fabienne Huber ◽  
Philipp M. Scheiwiller ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Health Effects ◽  
Oxygen Therapy ◽  
Ambient Air ◽  
Mean Difference ◽  
Chronic Obstructive ◽  
Pulmonary Hemodynamics ◽  
Obstructive Pulmonary Disease ◽  
Adverse Health Effects

IntroductionWe investigated whether nocturnal oxygen therapy (NOT) mitigates the increase of pulmonary artery pressure in patients during daytime with chronic obstructive pulmonary disease (COPD) traveling to altitude.MethodsPatients with COPD living below 800 m underwent examinations at 490 m and during two sojourns at 2,048 m (with a washout period of 2 weeks < 800 m between altitude sojourns). During nights at altitude, patients received either NOT (3 L/min) or placebo (ambient air 3 L/min) via nasal cannula according to a randomized crossover design. The main outcomes were the tricuspid regurgitation pressure gradient (TRPG) measured by echocardiography on the second day at altitude (under ambient air) and various other echocardiographic measures of the right and left heart function. Patients fulfilling predefined safety criteria were withdrawn from the study.ResultsTwenty-three COPD patients [70% Global Initiative for Chronic Obstructive Lung Disease (GOLD) II/30% GOLD III, mean ± SD age 66 ± 5 years, FEV1 54% ± 13% predicted] were included in the per-protocol analysis. TRPG significantly increased when patients traveled to altitude (from low altitude 21.7 ± 5.2 mmHg to 2,048 m placebo 27.4 ± 7.3 mmHg and 2,048 m NOT 27.8 ± 8.3 mmHg) difference between interventions (mean difference 0.4 mmHg, 95% CI −2.1 to 3.0, p = 0.736). The tricuspid annular plane systolic excursion was significantly higher after NOT vs. placebo [2.6 ± 0.6 vs. 2.3 ± 0.4 cm, mean difference (95% confidence interval) 0.3 (0.1 − 0.5) cm, p = 0.005]. During visits to 2,048 m until 24 h after descent, eight patients (26%) using placebo and one (4%) using NOT had to be withdrawn because of altitude-related adverse health effects (p < 0.001).ConclusionIn lowlanders with COPD remaining free of clinically relevant altitude-related adverse health effects, changes in daytime pulmonary hemodynamics during a stay at high altitude were trivial and not modified by NOT.Clinical Trial Registrationwww.ClinicalTrials.gov, identifier NCT02150590.

Sign in / Sign up

Export Citation Format

Share Document